Legislation


HB 17 (see companion bill SB 605) – Hawaii

Status: Inactive / Dead
Year Introduced: 2021
Link: https://www.capitol.hawaii.gov/measure_indiv.aspx?billtype=HB&billnumber=17&year=2022

Requires drug manufacturers to notify prescription drug benefit plans and pharmacy benefit managers if a proposed increase in the wholesale price of certain drugs would result in a sixteen per cent or more price increase over a two-year period. Requires the drug manufacturer to identify and report to the insurance commissioner information on certain drugs whose wholesale acquisition cost increases by a certain amount during a specified time frame.


Return to Database Search

© 2018-2019 The SLIHCQ DatabaseInitial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.

Associated Litigation:

No items found